Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Novartis/HGS' Albuferon ACHIEVEs Non-inferiority To Pegasys For Hepatitis C

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Solid results from the first of two key Phase III trials for Novartis/Human Genome Sciences’ hepatitis C candidate Albuferon (albinterferon alfa-2b) reduce the pressure by alleviating an earlier pulmonary safety concern, but the question remains whether quality of life and dosing benefits are enough for Albuferon to make headway in the interferon market.

You may also be interested in...

Follow-On Biologics Market Unfolding: Big Pharma Signals An Interest

Large pharmaceutical and biotechnology companies will start openly developing follow-on biologics once Congress passes legislation authorizing an abbreviated approval pathway, Cowen & Co. analyst Ken Cacciatore predicted

HGS Cuts High Dose Albuferon In Phase III After Increased Pulmonary Events

Lower 900 mcg dose of albinterferon alfa-2b is on track for hepatitis C filing in fall 2009, Human Genome Sciences says.

Human Genome Sciences Achieves Milestone For Albuferon Phase II Completion

HGS expects data from ACHIEVE pivotal program by spring 2009; global filings by fall 2009.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts